A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. We have developed, licensed, and acquired a portfolio of meaningfully differentiated products for use in the treatment of attention deficit hyperactivity disorder (“ADHD”) and moderate to severe pain. We commercialize our products, consisting of Jornay PM, Belbuca, Xtampza ER, Nucynta ER and Nucynta IR (collectively the “Nucynta Products”), and Symproic, in the United States. Jornay PM On September 3, 2024, we acquired Ironshore, which had developed and obtained commercial approval to market Jornay PM in the United States. Jornay PM is a central nervous system (“CNS”) stimulant prescription medicine that contains methylphenidate HCl, a Schedule II methylphenidate, which was approved by the U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 781M | 781M | 631M | 567M | 464M | 277M |
| Net Income | 63M | 63M | 69M | 48M | -25M | 72M |
| EPS | $1.73 | $1.73 | $1.86 | $1.29 | $-0.74 | $1.86 |
| Free Cash Flow | 328M | 328M | 203M | 274M | 123M | 102M |
| ROIC | 38.8% | 52.8% | 52.2% | 67.2% | 20.4% | 26.5% |
| Gross Margin | 59.3% | 59.3% | 59.8% | 57.5% | 45.2% | 54.4% |
| Debt/Equity | 0.81 | 0.81 | 1.07 | 1.38 | 0.77 | 0.73 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 180M | 180M | 170M | 167M | 33M | 18M |
| Operating Margin | 23.0% | 23.0% | 26.9% | 29.5% | 7.2% | 6.4% |
| ROE | 20.8% | 23.7% | 32.6% | 24.7% | -12.6% | 36.8% |
| Shares Outstanding | 36M | 36M | 37M | 37M | 34M | 38M |
COLLEGIUM PHARMACEUTICAL, INC passes 7 of 9 quality checks, indicating strong fundamentals.
COLLEGIUM PHARMACEUTICAL, INC trades at 20.6x trailing earnings, compared to its 15-year median P/E of 23.9x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 3.5x vs a median of 6.0x. The company's 5-year average ROIC is 43.8% with a gross margin of 55.2%. Total shareholder yield (buybacks) is 1.9%. At current prices, the estimated annualized return to fair value is +30.9%.
COLLEGIUM PHARMACEUTICAL, INC (COLL) has a current P/E ratio of 20.6, compared to its historical median P/E of 23.9. The stock is currently considered Fair based on its historical valuation range.
COLLEGIUM PHARMACEUTICAL, INC (COLL) has a 5-year average return on invested capital (ROIC) of 43.8%. This indicates strong capital allocation and a potential competitive advantage.
COLLEGIUM PHARMACEUTICAL, INC (COLL) has a market capitalization of $1.3B. It is classified as a small-cap stock.
COLLEGIUM PHARMACEUTICAL, INC (COLL) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 1.94%.
Based on historical P/E analysis, COLLEGIUM PHARMACEUTICAL, INC (COLL) appears fair. The current P/E of 20.6 is 14% below its historical median of 23.9. The estimated fair value CAGR (P/E method) is 26.0%.
COLLEGIUM PHARMACEUTICAL, INC (COLL) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
COLLEGIUM PHARMACEUTICAL, INC (COLL) reported annual revenue of $781 million in its most recent fiscal year, based on SEC EDGAR filings.
COLLEGIUM PHARMACEUTICAL, INC (COLL) has a net profit margin of 8.1%. This is a modest margin.
COLLEGIUM PHARMACEUTICAL, INC (COLL) generated $328 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
COLLEGIUM PHARMACEUTICAL, INC (COLL) has a debt-to-equity ratio of 0.81. This indicates moderate leverage.
COLLEGIUM PHARMACEUTICAL, INC (COLL) reported earnings per share (EPS) of $1.73 in its most recent fiscal year.
COLLEGIUM PHARMACEUTICAL, INC (COLL) has a return on equity (ROE) of 23.7%. This indicates the company generates strong returns for shareholders.
COLLEGIUM PHARMACEUTICAL, INC (COLL) has a 5-year average gross margin of 55.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 10 years of financial data for COLLEGIUM PHARMACEUTICAL, INC (COLL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
COLLEGIUM PHARMACEUTICAL, INC (COLL) has a book value per share of $8.30, based on its most recent annual SEC filing.